The views expressed in this manuscript represent the opinions of the authors and do not necessarily represent the views of the U.S. Food and Drug Administration.
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
Article first published online: 9 JUN 2012
Published 2012. This article is a US Government work and is in the public domain in the USA
Influenza and Other Respiratory Viruses
Volume 6, Issue 6, pages e129–e133, November 2012
How to Cite
Borders-Hemphill, V. and Mosholder, A. (2012), U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza and Other Respiratory Viruses, 6: e129–e133. doi: 10.1111/j.1750-2659.2012.00384.x
- Issue published online: 16 OCT 2012
- Article first published online: 9 JUN 2012
- Accepted 24 April 2012. Published Online 8 June 2012.
Please cite this paper as: Borders-Hemphill and Mosholder (2012) U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza and Other Respiratory Viruses 6(601), e129–e133.
Background The 2009 H1N1 influenza pandemic in the United States occurred from April 2009 to April 2010. The 2009 H1N1 influenza virus was susceptible to neuraminidase inhibitors (oseltamivir and zanamivir).
Objectives To characterize the 2009 H1N1 influenza pandemic in the United States from April 2009 to April 2010 using weekly influenza antiviral prescription utilization data and the CDC’s weekly reports of the number of visits for influenza-like-illnesses by the Influenza Sentinel Provider Surveillance Network.
Methods A proprietary outpatient data source used by the FDA, which captures adjudicated U.S. prescription claims for select influenza antiviral drugs, was used to conduct this analysis. Data were extracted weekly and analyzed for surveillance during the pandemic. Results were compiled at the end of the pandemic.
Results Oseltamivir has dominated the U.S. influenza antiviral market share of dispensed prescriptions since approval in October 1999 and was the primary influenza antiviral drug used during the 2009 H1N1 influenza pandemic. However, commercial availability of the suspension formulation of oseltamivir was reduced by high demand during the pandemic. Dispensed prescription trends of other influenza antiviral medications studied followed that those of oseltamivir, even antivirals for which the 2009 H1N1 strains showed resistance.
Conclusion Weekly prescription utilization of all influenza antivirals used to treat influenza during the seasonal influenza outbreak followed the same trend of weekly reports of the number of visits for influenza-like-illnesses (ILI) by the Influenza Sentinel Provider Surveillance Network. The ILI epidemic curve resembled dispensed antiviral prescription trends (both overall and stratified by age), providing some corroboration for the surveillance data.